Phosphatidylserine Capsule & Tablet OEM Spec Guide

Handing a phosphatidylserine formulation to an OEM without a specification set is an invitation to rework. The raw material behaves differently from commodity powders - it is a phospholipid, often used at low inclusion rates, sensitive to heat and oxidation, and carrying allergen and claim implications that reach the finished label. Whether the project is a two-piece capsule or a compressed tablet, the buyer's job is to define, in writing, what enters the plant, how the blend must perform, what the finished unit must weigh and deliver, and how long it must last. This guide sets out those specification layers for US and EU projects in the order they should be agreed.

Why OEM Specifications Come Before the Formulation

Many brand owners treat specifications as paperwork that follows formulation. For PS the sequence should run the other way, because specification decisions shape what the formulation can honestly claim and how it performs in production:

• The raw material spec determines active delivery: a 50% or 70% assay drives the label calculation, capsule count, and cost.
• The finished-product spec determines what quality agreement obligations the OEM accepts, and what evidence you can show an inspector or a retail partner.
• The claim strategy determines the label, and the label feeds back into required specifications - particularly in the EU, where permitted claims shape the product story from the start.

A practical rule for OEM engagements: before the first trial batch, the brand, the OEM, and the ingredient supplier should each sign off on one aligned specification chain - incoming raw material, in-process blend, and finished product - so that no party is interpreting the requirements alone.

Setting Incoming Raw Material Specifications for PS

The incoming specification is the OEM's gate for accepting your PS lot, so it must be specific enough to act on at goods-in. Beyond the basics, PS brings parameters that deserve explicit attention:

• Assay and identity: declared PS content with the analytical method stated, plus identity confirmation appropriate to a phospholipid.
• Particle size and flowability: a particle-size range consistent with the premix design prevents segregation and weight drift.
• Moisture and water activity: relevant both to dosing behavior and to oxidative stability in storage.
• Microbiological and contaminant limits: aligned to the market - US dietary supplement GMP expectations or EU food supplement expectations - rather than left at "per COA."
• Allergen and source statements: soy-derived PS carries soy allergen implications; sunflower-derived material changes both the allergen picture and some EU label considerations.

Two contract points complete the gate: require the OEM to verify against the specification rather than accepting the COA unread, and require advance notification of any supplier change in source, grade, or process, which flows through the whole specification chain.

Blend Uniformity and Premix Design

Phosphatidylserine is rarely the majority of a blend, and low-inclusion actives are where blend uniformity problems concentrate. A milligram-level PS dose dispersed into a many-hundred-kilogram batch can separate during movement if the premix design is left to chance.

The specification should therefore address:

• Premix strategy: whether PS is pre-diluted with a compatible carrier, and at what ratio, so each kilogram of premix carries a predictable PS load.
• Addition sequence and mixer type: agreed with the OEM's production team, since ribbon blenders, bin blenders, and V-blenders distribute low-inclusion actives differently.
• Sampling plan: sample the blend at defined points - beginning, middle, and end of discharge - not a single grab sample.
• Acceptance criteria: a relative standard deviation target agreed in advance - tight enough to support content uniformity, realistic for the mixer and batch size.

The blend's uniformity is the ceiling on finished-product uniformity: no filling or compression step can restore distribution the blender failed to create. When reviewing an OEM's master record, look for uniformity study evidence, not just the commitment.

Excipient Compatibility and Dosage Form Choice

The choice between a two-piece capsule and a compressed tablet is both a marketing decision and a stability decision, and PS makes the stability side unusually important.

Capsules are generally the lower-risk option for a phospholipid active: minimal compression, a protective shell, and simple fill of a powder or granulated premix. The main specification questions are fill-weight tolerances, shell material preferences (bovine, porcine, or plant-based - itself a label and market question), and whether a banding or sealing step is used to reduce oxygen ingress.

Tablets expose the blend to compression force, and phospholipids respond to heat, pressure, and moisture in ways that commodity actives do not. Key compatibility questions include:

• Which excipients are proposed: diluents, disintegrants, lubricants, and coatings all interact differently with a phospholipid surface.
• Whether antioxidants or protective processing (controlled granulation temperatures, low-moisture regimes) are needed.
• Whether the compression profile stays within limits the PS material tolerates, verified on trial batches rather than assumed.

A formal compatibility screening of PS alongside the proposed excipient set is a modest development cost and cheap insurance against a stability failure discovered after launch.

Weight Variation and Content Uniformity Targets

Finished-unit specifications translate blend performance into what each capsule or tablet actually delivers; ensure the OEM's spec covers both dimensions of dose control:

Weight variation can look excellent while PS content varies if the blend segregates, which is why content uniformity testing on finished units - at validation and at defined intervals - belongs in the specification, not in a verbal assurance. Agree the sampling and statistics in advance so a passing result means the same thing to both parties.

Stability Studies and Label Claim Boundaries

The OEM's stability protocol should define packaging (the same configuration destined for market), storage conditions including accelerated and long-term conditions, testing intervals, and attributes tested - PS content, oxidation indicators, moisture, and appearance among them. If an overage is used to guarantee label claim through end of shelf life, it should be documented, justified, and reflected in the label calculation, not hidden in the blend.

Label claims are the final specification, and the US and EU frameworks treat them differently:

• United States: labels may carry truthful structure/function statements with the customary disclaimer and a notification route, provided they describe effects on normal structure or function rather than disease. Claims discipline is a wording exercise the brand runs with its regulatory advisor.
• European Union: health claims must fall within EU-authorised claims and their conditions of use; for substances without an authorised claim, the label story typically stays with composition and general nutrition information.

The practical consequence for an OEM project is that the claim plan should be fixed before artwork is approved, because claims influence serving size presentation, target consumer positioning, and in some markets even the ingredient documentation the importer will need.

FAQ

Q: Which incoming parameters matter most when the OEM receives PS powder?

Assay and identity, particle size and flowability, moisture, oxidation indicators such as peroxide value, and contaminant limits aligned to the destination market. As a phospholipid, PS deserves as much oxidation attention as microbiology.

Q: Why is blend uniformity such a common failure point for PS products?

PS is typically a low-inclusion active, and low-inclusion ingredients segregate easily when premix design, addition sequence, and mixer settings are not engineered for them. A documented premix strategy and proper sampling plan prevent most issues before the filling line.

Q: Are capsules or tablets the safer dosage form for phosphatidylserine?

Capsules expose the material to less heat and compression, which suits an oxidation-sensitive phospholipid. Tablets are achievable with a compatible excipient design and verified compression conditions, but demand more development evidence, including compatibility screening.

Q: How do label claim rules differ between the US and EU for a PS supplement?

In the US, truthful structure/function statements with the customary disclaimer are a standard route. In the EU, health claims must fall within authorised claims and their conditions of use. Fix the claim plan with your regulatory advisor before approving artwork.

Conclusion

A successful PS capsule or tablet project is decided at the specification stage, not on the production floor. Incoming material parameters gate what enters the plant; premix design and blend uniformity determine what the process can deliver; excipient compatibility determines which dosage form is realistic; weight and content uniformity targets define what each unit must prove; and stability plus a claim plan determine what the label may say and for how long. Buyers who fix this chain with their OEM and ingredient supplier before the first trial batch launch faster, fail less, and carry a file that stands up to audit.

Sources

• U.S. Food and Drug Administration - Dietary Supplements: https://www.fda.gov/food/dietary-supplements
• U.S. National Institutes of Health, Office of Dietary Supplements: https://ods.od.nih.gov/
• European Food Safety Authority (EFSA): https://www.efsa.europa.eu/
• European Commission - Health and Food Safety: https://food.ec.europa.eu/
• EUR-Lex - Access to European Union Law: https://eur-lex.europa.eu/

Recommended next steps

• Review the Phosphatidylserine product page.
• Compare Soy PS and Sunflower PS.
• Check manufacturing proof and Quality & R&D.